ReviewCardiovascular & hematological disorders drug targets2026
Zerlasiran for Lipoprotein(a) Reduction: Mechanisms, Evidence, and Future Directions.
Review in Cardiovascular & hematological disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLipoprotein(a) [Lp(a)] is a genetically determined, independent risk factor for atherosclerotic cardiovascular disease (ASCVD). While it contributes significantly to residual cardiovascular risk, it remains under-recognized in clinical practice. In recent years, several novel drugs have been developed to lower Lp(a) levels, with multiple therapies currently under investigation.
methodsThis narrative review provides a summary of the structure and pathophysiological role of Lp(a) and current therapeutic approaches for its reduction. The primary focus is a critical analysis of published Phase 1 and Phase 2 clinical trial data on Zerlasiran, a GalNAc-conjugated siRNA developed to silence the LPA gene.
resultsZerlasiran has shown promising results in early clinical trials. In the Phase 1 trial, it achieved up to a 98% reduction in Lp(a) levels. In the Phase 2 trial, after a 36-week follow-up, Zerlasiran reduced Lp(a) levels by 80% or more in patients with cardiovascular disease, along with modest reductions in LDL-C and ApoB, and demonstrated a favorable safety profile. DISCUSSION: These findings suggest that Zerlasiran and similar siRNA therapies may address a significant unmet need in cardiovascular prevention by targeting a key component of residual risk. However, the long-term impact of Lp(a) lowering on clinical outcomes, such as Major Adverse Cardiovascular Events (MACE), remains to be determined.
conclusionZerlasiran represents a novel and highly targeted approach to managing elevated Lp(a), with the potential to shift future ASCVD prevention strategies. Pending Phase 3 trial results will be critical in establishing its role in clinical practice.
Indexed as
Identifiers
42152281What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.